Track topics on Twitter Track topics that are important to you
SANTA MONICA, Calif., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today reported financial results for the quarter ended June 30, 2015.
"This past quarter has been marked by a number of significant milestones. Most notably, we launched the first Company-sponsored clinical trial of our lead product candidate, KTE-C19," said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer. "We also entered into multiple collaborations, and expanded our manufacturing capabilities. In addition, we were very pleased to convene our first investor day on June 23rd, which allowed us to unveil new initiatives and highlight the progress of both our chimeric antigen receptor (CAR) and T cell receptor (TCR) programs."
Highlights of Developments in Second Quarter 2015
Second Quarter 2015 Financial Results
Conference Call and Webcast Details
Kite will host a live conference call and webcast today at 4:30pm Eastern Time to discuss its financial results and provide a general business update. The live webcast and subsequent replay may be accessed by visiting the Company's website at ir.kitepharma.com. Please connect to the Company's website at least 5-10 minutes prior to the live webcast to ensure adequate time for any necessary software download. Alternatively, please call (844) 856-8656 (U.S.) or (443) 877-4062 (international) to listen to the live conference call. The conference ID number for the live call is 98583072. Please dial in approximately 10 minutes prior to the call. The webcast will be available on the Company's website for two weeks following the event.
About Kite Pharma, Inc.
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous T-cell eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA.
Kite Pharma, Inc. Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the success and timing of the Phase 1/2 KTE-C19 clinical trial, the success of Kite's collaborations with bluebird bio and LLS, the success and timing of conducting additional clinical trials of KTE-C19 and of progressing a HPV TCR product candidate and Kite's 2015 financial guidance. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite's filings with the Securities and Exchange Commission, including without limitation in its Form 10-Q for the quarter ended June 30, 2015. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Kite assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
|KITE PHARMA, INC.|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|JUNE 30, 2015||DECEMBER 31,|
|Cash, cash equivalents, and marketable securities||$ 392,888||$ 367,040|
|Prepaid expenses and other current assets||10,406||1,330|
|Total current assets||403,294||368,370|
|Property and equipment, net||11,321||2,256|
|Intangible assets and goodwill, net||39,348||--|
|Total assets||$ 464,729||$ 370,753|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Accounts payable||$ 4,450||$ 2,320|
|Accrued expenses and other current liabilities||7,550||4,405|
|Total current liabilities||27,000||6,725|
|Deferred revenue, less current portion||39,078||--|
|Other non-current liabilities||6,456||1,439|
|Total stockholders' equity||376,174||362,589|
|Total liabilities and stockholders' equity||$ 464,729||$ 370,753|
|KITE PHARMA, INC.|
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
|(In thousands, except per share amounts)|
|THREE MONTHS||SIX MONTHS|
|ENDED JUNE 30,||ENDED JUNE 30,|
|Collaboration revenue||$ 4,403||$ --||$ 7,284||$ --|
|Research and development||16,588||7,424||25,849||9,516|
|General and administrative||9,774||3,716||18,945||4,786|
|Total operating expenses||26,362||11,140||44,794||14,302|
|Loss from operations||(21,959)||(11,140)||(37,510)||(14,302)|
|Other income (expense):|
|Other income (expense)||570||1||571||1|
|Total other income (expense)||1,067||(6,218)||1,531||(6,197)|
|Series A preferred stock dividend||--||(532)||--||(1,089)|
|Net loss attributable to common stockholders||$ (20,892)||$ (17,890)||$ (35,979)||$ (21,588)|
|Net loss per share, basic and diluted||$ (0.48)||$ (2.27)||$ (0.84)||$ (3.20)|
|Weighted-average shares outstanding, basic and diluted||43,249||7,890||42,860||6,737|
Note Regarding Use of Non-GAAP Financial Measures
Kite provides non-GAAP net loss and non-GAAP net loss per share that include adjustments to GAAP figures. These adjustments to GAAP net loss exclude non-cash stock-based compensation expense. Kite believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Kite's financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of Kite's operating results. In addition, these non-GAAP financial measures are among the indicators Kite's management uses for planning purposes and measuring Kite's performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by Kite may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Please refer below for a reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures.
|KITE PHARMA, INC.|
|Reconciliation of GAAP to Non-GAAP Net Loss|
|(In thousands, except per share amounts)|
|THREE MONTHS ENDED||SIX MONTHS ENDED|
|JUNE 30,||JUNE 30,|
|Net loss attributable to common stockholders – GAAP||$ (20,892)||$ (17,890)||$ (35,979)||$ (21,588)|
|Non-cash stock-based compensation expense||9,381||7,044||16,058||7,241|
|Net loss attributable to common stockholders – Non-GAAP||$ (11,511)||$ (10,846)||$ (19,921)||$ (14,347)|
|Net loss per share attributable to common stockholders, basic and diluted – GAAP||$ (0.48)||$ (2.27)||$ (0.84)||$ (3.20)|
|Non-cash stock-based compensation expense per share||0.22||0.89||0.37||1.07|
|Net loss per share attributable to common stockholders, basic and diluted – Non-GAAP||$ (0.26)||$ (1.38)||$ (0.47)||$ (2.13)|
|Weighted average common shares outstanding, basic and diluted||43,249||7,890||42,860||6,737|
CONTACT: Kite Pharma Cynthia M. Butitta Chief Financial Officer and Chief Operating Officer 310-824-9999 For Media: Justin Jackson For Investor Inquiries: Lisa Burns and Carol Werther Burns McClellan 212-213-0006 firstname.lastname@example.org email@example.com firstname.lastname@example.orgNEXT ARTICLE
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...